Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Epionce Melanolyte Skin Brightening System is a botanical-based topical regimen developed by Episciences, Inc. for the treatment of hyperpigmentation and melasma. The system typically comprises two products, such as the Melanolyte Tx and Melanolyte Serum, which utilize a synergistic blend of herbal ingredients—including licorice root, turmeric, and white water lily—to inhibit melanogenesis and reduce skin inflammation. Unlike traditional hydroquinone-based therapies, the Epionce system is designed to improve skin clarity and tone while strengthening the skin barrier and minimizing irritation. Clinical studies, including those conducted by the Sadick Research Group, have evaluated its efficacy as a non-prescription alternative to 4% hydroquinone for mottled hyperpigmentation and melasma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Epionce Melanolyte Skin Brightening System.